Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
licartin + sorafenib
- Development stage
- Preclinical
- Lead developer
- China Isotope & Radiation Corporation
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous (Licartin), Oral (sorafenib)
01
Overview
Licartin + sorafenib is a combination therapy used primarily in the treatment of advanced hepatocellular carcinoma (HCC). Licartin is the brand name for iodine-131 metuximab, a radiolabeled monoclonal antibody targeting CD147 (also known as HAb18G/CD147) on tumor cells. It delivers targeted radiation to liver cancer cells. Sorafenib is an oral small molecule multikinase inhibitor that targets Raf kinase and several receptor tyrosine kinases involved in tumor cell proliferation and angiogenesis, including VEGFR-1/2/3 and PDGFR-β. The combination aims to enhance antitumor efficacy by combining targeted radiotherapy with molecular inhibition of tumor growth and angiogenesis[1][5][8].
- Brand names
- Nexavar
- Other names
- 利卡汀 + 索拉菲尼Iodine-131 metuximab + sorafenib131I-metuximab + sorafenib
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)BSG (Basigin)FGFR1 (Fibroblast growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on licartin + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on licartin + sorafenib.